|
Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field Ablation
CARDIFF-BY-THE-SEA, Calif., Feb. 6, 2026 /PRNewswire/ -- Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, today announced the presentation of late breaking clinical trial data from the first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026, held February 5–7 in Boston.
Field PULSE evaluates a novel high-voltage, sub-second pulsed field waveform delivered through Field Medical's FieldForce™ Ablation System and Catheter, a focal, contact-sensing catheter, enabling instantaneous ablation through point-by-point energy delivery without reliance on prolonged tissue-catheter contact. The study was selected for a Late Breaking Clinical Trial (LBCT) presentation.
"By eliminating the need for sustained tissue-catheter contact, sub-second pulsed field delivery enables both efficient point-by-point ablation and individualized lesion sets," said Vivek Y. Reddy, M.D., principal investigator of Field PULSE and electrophysiologist at Mount Sinai, New York. "This approach preserves the flexibility physicians expect from focal ablation while delivering the procedural efficiency associated with pulsed field technologies."
Study Highlights
- Instantaneous energy delivery: Lesions created in less than 200 milliseconds, enabling rapid point-by-point ablation
- Procedural efficiency: Median bilateral pulmonary vein isolation (PVI) time of 12.5 minutes, with the fastest case completed in 7.7 minutes
- PVI durability: Remapping demonstrated progressive improvement in PVI durability with the optimized waveform
- By vein: 94.2%
- By patient: 84.6%
- Safety outcomes:
- No device-related serious adverse events
- No acute kidney injury, reported phrenic nerve palsy or clinically relevant hemolysis
- Among patients evaluated by brain MRI (n=14), no silent cerebral lesions (DWI+/FLAIR+) were observed
These findings extend Field Medical's body of clinical evidence of its high-voltage focal PFA approach beyond ventricular arrhythmias and into the development of therapy for atrial fibrillation (AF). Together with previously reported six-month first-in-human ventricular tachycardia (VT) data, the results support the emergence of a versatile ablation platform for all chambers of the heart, designed to enable focal PFA across atrial and ventricular substrates while preserving procedural efficiency.
"The Field PULSE results reinforce our approach of deliberately architecting focal PFA to address the fundamental limitations of existing methods, then validating its application through data," said Steven Mickelsen, M.D., founder and chief technology officer of Field Medical. "By delivering each ablation point in a fraction of a second, we reduce dependence on prolonged catheter stability, limit the impact of cardiac motion and establish a platform approach for treating complex arrhythmias."
The Field PULSE data were presented during the Late Breaking Clinical Trials Session I at AF Symposium 2026. Field Medical will be featured on Friday, February 6, from 7:30–8:30 a.m. during a scientific session on the biophysics of PFA for AF, including a presentation titled Maximizing Lesion Depth Using High Voltage PFA Waveform by Kenneth Ellenbogen, M.D., and during Case Transmission Session 6 on Saturday, February 7, from 7:30–9:30 a.m., highlighting AF Ablation Using a High-Voltage Field Medical PFA Catheter, presented by Vivek Reddy, M.D., using the FieldForce Ablation System and FieldForce Ablation Catheter.
About FieldForce™ Ablation System
The FieldForce Ablation System is a focal, contact-sensing PFA system built on proprietary FieldBending™ technology to deliver targeted, high-intensity electric fields using a novel pulsed energy delivery strategy. Designed to support both atrial and ventricular ablation, the system serves as a universal ablation platform for the heart and beyond. The FieldForce system is designed to enable targeted and tailored ablation treatment while platform features focus on procedural efficiency.
About Field Medical®, Inc.
Founded in 2022 by Steven Mickelsen, M.D., Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce Ablation System integrates a focal catheter design with proprietary FieldBending energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X, and YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.
Media Contact
Holly Windler
619.929.1275
holly.windler@gmail.com
media@fieldmedicalinc.com
Photo - https://mma.prnasia.com/media2/2878123/Field_Medical_Ablation_System.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg?p=medium600
Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and Efficient Point-by-Point Pulsed Field Ablation
CARDIFF-BY-THE-SEA, Calif., Feb. 6, 2026 /PRNewswire/ -- Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, today announced the presentation of late breaking clinical trial data from the first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026, held February 5–7 in Boston.
Field PULSE evaluates a novel high-voltage, sub-second pulsed field waveform delivered through Field Medical's FieldForce™ Ablation System and Catheter, a focal, contact-sensing catheter, enabling instantaneous ablation through point-by-point energy delivery without reliance on prolonged tissue-catheter contact. The study was selected for a Late Breaking Clinical Trial (LBCT) presentation.
"By eliminating the need for sustained tissue-catheter contact, sub-second pulsed field delivery enables both efficient point-by-point ablation and individualized lesion sets," said Vivek Y. Reddy, M.D., principal investigator of Field PULSE and electrophysiologist at Mount Sinai, New York. "This approach preserves the flexibility physicians expect from focal ablation while delivering the procedural efficiency associated with pulsed field technologies."
Study Highlights
- Instantaneous energy delivery: Lesions created in less than 200 milliseconds, enabling rapid point-by-point ablation
- Procedural efficiency: Median bilateral pulmonary vein isolation (PVI) time of 12.5 minutes, with the fastest case completed in 7.7 minutes
- PVI durability: Remapping demonstrated progressive improvement in PVI durability with the optimized waveform
- By vein: 94.2%
- By patient: 84.6%
- No device-related serious adverse events
- No acute kidney injury, reported phrenic nerve palsy or clinically relevant hemolysis
- Among patients evaluated by brain MRI (n=14), no silent cerebral lesions (DWI+/FLAIR+) were observed
These findings extend Field Medical's body of clinical evidence of its high-voltage focal PFA approach beyond ventricular arrhythmias and into the development of therapy for atrial fibrillation (AF). Together with previously reported six-month first-in-human ventricular tachycardia (VT) data, the results support the emergence of a versatile ablation platform for all chambers of the heart, designed to enable focal PFA across atrial and ventricular substrates while preserving procedural efficiency.
"The Field PULSE results reinforce our approach of deliberately architecting focal PFA to address the fundamental limitations of existing methods, then validating its application through data," said Steven Mickelsen, M.D., founder and chief technology officer of Field Medical. "By delivering each ablation point in a fraction of a second, we reduce dependence on prolonged catheter stability, limit the impact of cardiac motion and establish a platform approach for treating complex arrhythmias."
The Field PULSE data were presented during the Late Breaking Clinical Trials Session I at AF Symposium 2026. Field Medical will be featured on Friday, February 6, from 7:30–8:30 a.m. during a scientific session on the biophysics of PFA for AF, including a presentation titled Maximizing Lesion Depth Using High Voltage PFA Waveform by Kenneth Ellenbogen, M.D., and during Case Transmission Session 6 on Saturday, February 7, from 7:30–9:30 a.m., highlighting AF Ablation Using a High-Voltage Field Medical PFA Catheter, presented by Vivek Reddy, M.D., using the FieldForce Ablation System and FieldForce Ablation Catheter.
About FieldForce™ Ablation System
The FieldForce Ablation System is a focal, contact-sensing PFA system built on proprietary FieldBending™ technology to deliver targeted, high-intensity electric fields using a novel pulsed energy delivery strategy. Designed to support both atrial and ventricular ablation, the system serves as a universal ablation platform for the heart and beyond. The FieldForce system is designed to enable targeted and tailored ablation treatment while platform features focus on procedural efficiency.
About Field Medical®, Inc.
Founded in 2022 by Steven Mickelsen, M.D., Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce Ablation System integrates a focal catheter design with proprietary FieldBending energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X, and YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.
Media Contact
Holly Windler
619.929.1275
holly.windler@gmail.com
media@fieldmedicalinc.com
Photo - https://mma.prnasia.com/media2/2878123/Field_Medical_Ablation_System.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg?p=medium600
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Field Medical Presents Late Breaking Field PULSE Trial Data at AF Symposium 2026
|
DUBAI, UAE, Feb. 6, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has introduced two easy-to-use account modes on Bybit TradFi, designed to help both new and experienced users start trading traditional assets with confidence.
The new account modes, Zero-Fee mode and Tight-Spread mode, give users a clear choice in how they access markets such as gold, FX, and stocks, depending on their cost preferences and trading experience. Both operate on industry-standard foreign exchange brokerage models, with the primary distinction being how transaction costs are applied and displayed.
Under Zero-Fee mode, users can trade gold and other TradFi products with no separate commission charges, as trading costs are incorporated into the spread. This simplified structure makes it especially beginner-friendly, allowing anyone to get started right away without needing to manage complex fee calculations. Tight-Spread mode, by contrast, offers narrower spreads with a transparent commission structure, a format typically favored by more active traders who prioritize precision pricing and tighter market execution.
To make onboarding seamless, Zero-Fee mode is set as the default option for all new TradFi users, enabling them to start trading immediately. Eligible users may switch to Tight-Spread mode at any time, provided they accumulate a total TradFi deposit of at least 3,000 USDT in their TradFi account and have no open positions or pending orders at the time of the switch. Account mode changes can be completed through both the Bybit app and web platform within the TradFi trading interface.
The launch builds on a year of significant TradFi product expansion. In 2025, Bybit introduced U.S. stock CFD trading, expanded easy access to gold and FX trading under the unified TradFi banner, and completed web integration to enable seamless web-based trading. These developments reinforce Bybit TradFi's commitment to making traditional markets more accessible to everyday traders.
The introduction of dual account modes reflects Bybit TradFi's continued focus on lowering the barrier to entry while still supporting advanced trading strategies, maintaining transparency and consistency in pricing structures. Additional details on TradFi trading and account functionality are available on Bybit's official website.
#Bybit / #CryptoArk
Bybit TradFi is powered by Infra Capital (Mauritius FSC licensed). The service is now available to eligible users through the official Bybit app and website. Bybit TradFi is not available to residents of the European Economic Area, among other restrictions. For details of regional limitations, terms and conditions, and user eligibility, users may visit Bybit TradFi. Trading comes with risk.
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
DUBAI, UAE, Feb. 6, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has introduced two easy-to-use account modes on Bybit TradFi, designed to help both new and experienced users start trading traditional assets with confidence.
The new account modes, Zero-Fee mode and Tight-Spread mode, give users a clear choice in how they access markets such as gold, FX, and stocks, depending on their cost preferences and trading experience. Both operate on industry-standard foreign exchange brokerage models, with the primary distinction being how transaction costs are applied and displayed.
Under Zero-Fee mode, users can trade gold and other TradFi products with no separate commission charges, as trading costs are incorporated into the spread. This simplified structure makes it especially beginner-friendly, allowing anyone to get started right away without needing to manage complex fee calculations. Tight-Spread mode, by contrast, offers narrower spreads with a transparent commission structure, a format typically favored by more active traders who prioritize precision pricing and tighter market execution.
To make onboarding seamless, Zero-Fee mode is set as the default option for all new TradFi users, enabling them to start trading immediately. Eligible users may switch to Tight-Spread mode at any time, provided they accumulate a total TradFi deposit of at least 3,000 USDT in their TradFi account and have no open positions or pending orders at the time of the switch. Account mode changes can be completed through both the Bybit app and web platform within the TradFi trading interface.
The launch builds on a year of significant TradFi product expansion. In 2025, Bybit introduced U.S. stock CFD trading, expanded easy access to gold and FX trading under the unified TradFi banner, and completed web integration to enable seamless web-based trading. These developments reinforce Bybit TradFi's commitment to making traditional markets more accessible to everyday traders.
The introduction of dual account modes reflects Bybit TradFi's continued focus on lowering the barrier to entry while still supporting advanced trading strategies, maintaining transparency and consistency in pricing structures. Additional details on TradFi trading and account functionality are available on Bybit's official website.
#Bybit / #CryptoArk
Bybit TradFi is powered by Infra Capital (Mauritius FSC licensed). The service is now available to eligible users through the official Bybit app and website. Bybit TradFi is not available to residents of the European Economic Area, among other restrictions. For details of regional limitations, terms and conditions, and user eligibility, users may visit Bybit TradFi. Trading comes with risk.
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Bybit TradFi Launches Beginner-Friendly Account Modes Offering Easy Access to Gold Trading and Zero Fees
